Navigation Links
Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the initiation of a Phase I clinical trial of the Company's lead drug candidate ME-143 in patients with refractory solid tumors. The trial is being conducted in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, following the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) last month.

This Phase I dose-escalation trial will evaluate the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors. In addition, the trial is designed to characterize the pharmacokinetic profile of intravenous ME-143 and describe any preliminary clinical anti-tumor activity observed. The open-label trial is expected to enroll up to 24 patients with final data collected by the second quarter of 2012.

"We are excited to begin treating patients with ME-143, a promising drug candidate that has demonstrated anti-tumor activity in pre-clinical studies," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "Together with the Sarah Cannon Research Institute, we will be obtaining important information regarding dosing, safety and potential efficacy of intravenous ME-143 over the next several months, which will inform the design of our randomized Phase II clinical trials in combination with standard-of-care chemotherapy."

Additional information regarding this trial, entitled "Phase I Open Label Multicenter Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 in Patients with Refractory Solid Tumors," including enrollment criteria and site information, is available on the U.S. National Institutes of Health (NIH) clinical trials database at

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
2. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
3. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
4. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
5. Marshall Edwards Announces Private Placement
6. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
7. Marshall Edwards Receives Positive Response From NASDAQ
8. Marshall Edwards to Host Annual Meeting of Stockholders
9. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
10. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
11. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... PITTSBURGH , July 27, 2015  Mylan N.V. (NASDAQ: ... extraordinary general meeting of shareholders in connection with its proposed ... at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 ... Among other agenda items at the extraordinary general meeting, Mylan ... 2:107a of the Dutch Civil Code, of the acquisition of ...
(Date:7/27/2015)... 27, 2015  The fairness of the proposed acquisition ... Jude Medical ("St. Jude") is the subject of an ... rights law firm.  The investigation is focusing on possible ... by the Board of Directors of THOR for agreeing ... 2015, the Company announced it had reached a definitive ...
(Date:7/27/2015)... 27, 2015  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Monday, August ... will lead the call.  Date:Monday, ... 507-2598Pass Code: 68380312 Webcast, including Replay and ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... ... 2015 , ... There has been much discussion in Washington, D.C. ... often overlooked is the over 740,000 miles of municipal sewer lines designed ... facilities. According to the American Society of Civil Engineers , the average age ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step ... Center located at Gary Avenue and Lies Road in Carol Stream. All are welcome. ... awareness, and provide education and help to support individuals and families affected by a brain ...
(Date:7/28/2015)... AURORA, Colo. (PRWEB) , ... July 28, 2015 ... ... education provider to offer online RN to BSN cohorts for Geisinger ... The education partnership provides GHS diploma and associate degree prepared nurses with access ...
(Date:7/28/2015)... ... , ... Scientel is thrilled to announce that they been accepted ... McHenry Convention Center in San Jose, Ca. Scientel will be participating as a Silver ... and the industry’s first polymorphic database will address the critical need of efficiently storing ...
Breaking Medicine News(10 mins):Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 2Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 3
... and Amortization Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, ... "the Group"), one of the leading Mexican,distributors of pharmaceutical products, ... other products,announces its consolidated financial and operating results for the ...
... WASHINGTON, Feb. 26 The following is a,statement ... Tobacco-Free,Kids:, All Nebraska workplaces, including restaurants, bars ... 2009, thanks to,legislation overwhelmingly approved by the Legislature ... Dave Heineman. Governor Heineman and the,Legislature have delivered ...
... Schnitzer West announced today,that one of the country,s most ... in The Shops at The Bravern in downtown Bellevue ... meet the needs of approximately 2,300,Microsoft employees who will ... beginning this fall., DavidBartonGym will offer Barton,s world ...
... Over 200,of MemorialCare,s top leaders will participate in a ... for Humanity of Orange County. The,home will be renovated ... palsy and is confined to a wheelchair. Halls will ... be given a "makeover" with,upgrades throughout., (Photo: ...
... designed to enhance patient acceptance and ... ... a prescription,laxative product that treats acute and chronic constipation, may be ... MiraLAX(R) and generic PEG 3350 products. Marketed in the,U.S. by Cumberland ...
... for His Support of a New ... Playground, LAS ... social service agency, during a ceremonial session of,the Las Vegas City Council meeting. ... playground fundraising,efforts., Mayor Goodman was presented with a plaque of appreciation by ...
Cached Medicine News:Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:Nebraska's New Smoke-Free Law is Historic Win for Health 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3Health News:MemorialCare Sponsors Habitat for Humanity Santa Ana Home 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 2Health News:Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products 3
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
Disposable Cannula Cuffless Tracheostomy Tubes...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: